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Opinion statement
Despite the development of several injectable or oral treatments for relapsing-remitting
multiple sclerosis (RRMS), it remains difficult to treat patients with aggressive disease,
and many of these continue to develop severe disability. During the last two decades au-
tologous hematopoietic stem cell transplantation (aHSCT) has been explored with the goal
to eliminate an aberrant immune system and then re-install a healthy and tolerant one from
hematopoietic precursor cells that had been harvested from the patient prior to chemo-
therapy. Clinical studies have shown that aHSCT is able to completely halt disease activity
in the majority of patients with aggressive RRMS. Research on the mechanisms of action
supports that aHSCT indeed leads to renewal of a healthy immune system. Below we will
summarize important aspects of aHSCT and mention the currently best-examined regimen.
Introduction
Multiple sclerosis (MS) is considered a prototypical T
cell-mediated autoimmune disease that develops
based on a complex genetic background and addition-
al environmental triggers such as infection with Ep-
stein Barr virus (EBV), low vitamin D3 levels, and
smoking [1, 2]. Pathogenetically, MS is characterized by
inflammatory lesions in the central nervous system
(CNS), which leads to demyelination, incomplete
remyelination, and also to neuronal/axonal damage
and glial proliferation. Clinically,MS causes bouts of neu-
rological deficits, in most instances problems of vision,
sensory- andmotor deficits, but also ataxia, and compro-
mise of neurocognitive and autonomous functions. Re-
lapses usually resolve after days and weeks during
earlier stages of the disease, but remit only incompletely
or not at all later. MS is heterogeneous in almost every re-
spect including clinical presentation, disease course, im-
aging findings, the extent and destructiveness of
inflammation, and also of neurodegenerative aspects
such as demyelination and loss of axons or CNS tissue
in general, and finally the response to treatment.
The development of treatments for MS has been very
successful, eight drugs are currently available and multi-
ple others either already filed for approval or in late stage
clinical development. However, due to the chronic na-
ture of MS, all of these need to be given for long times
or forever. Further, all of these have side effects and some
of them very serious ones, and, depending on their route
of administration, some treatments compromise quality
of life. Also, most of these are very expensive, and lead to
substantial socioeconomic burden. All currently avail-
able disease-modifying treatments of MS are only effec-
tive during the earlier stages of disease, when
autoimmune inflammation drives the disease process
and before toomuchCNS tissue is irreversibly damaged.
The current goals of treatment are therefore to institute
MS treatment as early as possible and ideally to halt
the disease process completely or at least for as long as
possible. In a relatively small percentage of patients MS
is so active and relapses orCNS lesions occur so frequent-
ly that one has to escalate treatment intensity and start
treatments that are more effective, but also have more
side effects. Despite these measures relapses can some-
times not be halted, and it is in these patients where
we need additional options.
Autologous hematopoietic stem cell transplantation
(aHSCT) has evolved as one if not the best option to treat
aggressive forms of MS, although acceptance among
neurologists is still low. The reasons for this include
the fact that mostly secondary- or primary progressive
MS patients have been treated in earlier studies, and the-
se respondedonly incompletely and/orweremoreprone
to develop complications [3]. Further, the prevailing per-
ception is that risk is still very high, ie, mortality ranges
up to 10 %, however in recent years, aHSCT has ad-
vanced substantially, and transplant-related mortality
has been between 1 %–1.5 % since 2000 with the
BEAM-ATG regimen [4]. Through tight collaboration be-
tween hematologists/transplant specialists and neurolo-
gists aHSCT is now more standardized, mortality is
within the range of the most active approved therapy,
ie, mitoxantrone, the efficacy is likely superior to all oth-
er available treatments, its mechanisms are better under-
stood, and aHSCT is probably the only treatment of MS
that has to be applied only once with no further need for
therapy in the majority of patients, provided that they
have been selected carefully. Despite all this, formal
proof through a phase III clinical trial is still lacking
mainly because testing such a treatment regimen is not
supported by pharmaceutical industry, but pursued by
academic investigators. Below, we will summarize the
most important aspects of aHSCT and give a recommen-
dation, how it should be applied in patients with aggres-
sive disease, which is based on consensus meetings and
continuous discussions between investigators in Europe
and North America.
MS treatment landscape
Current treatments of multiple sclerosis aim at reducing relapses and preventing
or slowing progression of neurological disability in the most common form of
MS,which at the timeof first diseasemanifestation such as for example optic neu-
ritis ormyelitis is called clinically isolated syndrome (CIS). Once a second relapse
occurs that affects a different functional system of the central nervous system
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(CNS) or when imaging findings indicate dissemination in time and space, the
diagnosis of relapsing-remittingMS (RRMS) is made, which evolves into second-
ary progressive MS (SPMS) with or without relapses after various time intervals.
CIS-RRMS-SPMS affects 80 %–85 % of patients, and only approximately 10 %
of cases show disease progression from the beginning (primary progressive MS;
PPMS). With respect to disease severity MS runs a benign course and never leads
to substantial disability in aminority of patients, and, also relatively rarelyMS can
be aggressive and lead to death in a few years. MS relapses are treated with high
dose intravenous or oral corticosteroids or, in the case of incomplete responses
and severe relapses, by plasmapheresis. Available disease modifying drugs are ei-
ther immunomodulatory or immunosuppressive and hence are effective during
the inflammatory, relapsing-remitting phase of the disease.
Different from other neurological diseases such as stroke or Alzheimer’s dis-
ease, drug development forMS has been very successful, andwe have now several
first-line treatments for RRMS. Interferon-β (IFN-β) and glatiramer-acetate (GA)
are already approved for up to two decades and have moderate efficacy and a fa-
vorable, well-known and benign side effect profile. Depending on the country, a
recently introduced oral compound, fingolimod, is available as first-line or sec-
ond-line andorally administereddrug. Fingolimod, a sphingosin-1phosphate re-
ceptor agonist, is considerablymore effective than IFN-β andGA and overall also
well tolerated. Other oral medications are either already approved and will be
available shortly (teriflunomide) or have been filed for approval after successful
phase III testing (dimethyl-fumarate; laquinimod). The most effective currently
available treatment is natalizumab, a humanized monoclonal antibody against
CD49d/very late antigen-4 (VLA-4), which is generally also well tolerated, but
has led to progressive multifocal leukoencephalopathy (PML), an opportunistic
and often fatal infection of the brain by the polyoma virus JC, in over 300patients
so far. A chemotherapeutic agent,mitoxantrone, is used as second-line therapy for
more severe RRMS and also for SPMS [5]. Mitoxantrone can only be given for a
very limited period of time due to its cardiac toxicity, and secondary leukemias
have occurred in up to 2.8%ofMSpatients treatedwithmitoxantrone. Regarding
injectable or infusible compounds, several monoclonal antibodies have finished
or are about to finish phase III clinical testing (anti-CD25, daclizumab; anti-
CD20, ocrelizumab) or have already been filed for approval (anti-CD52,
alemtuzumab). Furthermore, various other drugs and treatment ap-
proaches including oral- and injectable compounds, tolerization strate-
gies with peptides, peptide-coupled cells, or inactivated autoreactive T
cells, immunomodulation with mesenchymal stem cells, and immune re-
constitution with autologous hematopoietic stem cells (aHSCT) are cur-
rently being tested at different stages of clinical development.
Based on longer time follow-up data from testing IFN-β in CIS, which
demonstrated that the conversion to RRMS can be prolonged and that dis-
ability evolution can also be slowed by early treatment [6, 7], the prevailing
tendency today is to treat patients early. Another strong argument for early
treatment is that CNS tissue, despite its ability of functional compensation
of certain deficits, has only a very limited capacity for repair at the structural
level. As a consequence, MS treatments are most effective during the inflam-
matory RRMS phase of the disease and have little or no influence once a cer-
tain disability level and CNS damage have occurred and when SPMS has
begun. It is generally accepted that immunomodulatory or even immuno-
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suppressive treatments are not effective in SPMS, and that it is imperative
therefore to initiate treatment as early as possible in order to prevent disabil-
ity accrual as much as possible. However, depending on the drug label and
approval of the various therapies in different countries, it may not be possi-
ble to start treatment with the most effective drug/s. Furthermore, since MS
primarily affects young adults and is a chronic, life-long disease, the route
of administration and adverse event profile of the respective treatment, the
patient’s wish to have children and other aspects have to be taken into con-
sideration. Some of the above drugs, eg, mitoxantrone or alemtuzumab, have
long-lasting effects on the hematopoietic system or carry the risk of secondary
malignancies and cardiac damage (mitoxantrone) or of secondary autoimmune
diseases (alemtuzumab).Natalizumabmay lead to PMLwith increasing risk fol-
lowing 2 years of treatment or even higher risk following prior treatment with
chemotherapeutic agents such as mitoxantrone. Hence, treatment decisions,
ie, how to begin and escalate therapy and which drug can be given or not after
which prior medications, are not easy and need to take into account the severity
and prognosis of MS in the individual patient, the prior treatment history, and
the long-term adverse profile of the drugs and treatments.
Autologous hematopoietic stem cell transplantation—current
status
As reviewed by Saccardi and Mancardi [4], numerous aspects of aHSCT in-
cluding different stem cell mobilization and conditioning regimens, which
patients are best suited, the percentage of progression-free survivors, and
which factors contribute to risk have been examined in detail. More than
500 MS patients have received aHSCT in Europe alone in the last 20 years,
and follow-up for substantial fraction of these is longer than 10 years. A joint
study of the European and American Bone Marrow Transplantation Societies
on long-term outcomes after HSCT in MS is currently ongoing. Problems
with these data derive from the heterogeneity of the treated patients with re-
spect to disease course and stage, from the fact that most studies have been
open, uncontrolled trials, and from differences in the transplant regimens that
have been used. Nevertheless, the most important aspects, ie, patient eligibility,
transplant regimen, and also themechanistic understanding have advanced sub-
stantially, and a consensus has been reached between European and North
American investigators that aHSCT is best applied in patients of 45 years or
younger, within the first 5 years after diagnosis, with aggressive RRMS, and using
the BEAM-ATG regimen. Below, we will provide more detail regarding the most
important aspects of patient selection and transplant regimen.
Patient eligibility criteria—who is a candidate?
From the above reasons treatment responses to aHSCT have been less
clear in SPMS patients, and the fraction of patients, who show sustained
improvement for more than one EDSS point is much larger in RRMS
patients [8]. There is currently no doubt that aHSCT is most effective
in highly active RRMS patients. Identification of MS patients, who are
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best suited for aHSCT, is one of the most important aspects for success-
ful treatment. Patients should still be in the early stages of the disease,
ie, ideally within 5 years after diagnosis, and have a high risk for rapid
disease progression, ie, have aggressive MS [9]. Reliable prognostic pre-
dictors for an aggressive course are, however, still lacking, and so far
the best approach is to combine clinical relapse activity, MRI activity
and failure to respond to first-line- and/or second line treatment. In a
recent manuscript that summarized the consensus among specialists,
who pursue aHSCT, highly active RRMS has been defined as follows:
& at least one severe clinical relapse (ΔEDSS≥1 with Functional Severity
Score (FSS) ≥2 in motor, cerebellar, or brain stem function in the
year prior to evaluation,
& ≥1 gadolinium-positive (Gd+) lesion of diameter ≥3 mm or
accumulation of ≥0.3 T2 lesions/month in 2 consecutive MRI 6–
12 months apart.
Furthermore patients qualify for aHSCT after failure of conventional best
treatment, which is currently natalizumab. Whether aHSCT can already
be considered after failure of first line therapy and prior to further esca-
lation steps is still under discussion [9], but unlikely to be accepted by a
broader number of MS neurologists before formal proof of the superior-
ity of aHSCT over most active conventional therapies has been provided.
Patients considered for aHSCT should be younger than 45 years. This is based
on increasing transplant-related mortality in patients aged over 40 years [3],
whichmaybe related to immunosenescence and/or less efficient immune recon-
stitution in MS patients above this age [3]. Furthermore, patients over 40 years
are at increased risk to shift quicker to the secondary progressive phase of the dis-
ease [10], duringwhich the benefit of aHSCT is clearly reduced. The path of treat-
ment escalation and eligibility criteria are briefly summarized in Fig. 1.
Stem cell mobilization and conditioning regimen
The main assumption of how aHSCT acts is that an aberrant immune
system that underlies the autoimmune disease is eliminated by chemo-
therapeutic drugs and subsequently a new and again tolerant immune
system is installed by infusing the patient with his/her own hematopoi-
etic stem cells that have been collected prior to conditioning. Along this
rationale one important question is how intense and complete the con-
ditioning regimen has to be, ie, if most of hematopoietic stem cells need
to be eliminated (myeloablative) or if it is sufficient to deplete lympho-
cytes (lymphoablative). The former absolutely requires stem cell rescue
and carries substantially higher risk. Several transplant regimens includ-
ing more intense ones with whole body irradiation, with different che-
motherapeutic agents, changes in graft mobilization and/or manipulation,
or also less intensive lymphoablative regimens have been explored during
the last 20 years (for review, see reference [4]). Careful assessment and con-
tinuous discussion among aHSCT specialists have led to consensus that the
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best experience currently exists for the BEAM-ATG regimen, which has been
used most frequently in Europe in the last 15 years. Peripheral Blood
Haematopoietic Stem Cells (PBSC) are collected by leukapheresis after mo-
bilization by cyclophosphamide (2-4 g/m2 total dose over 1–2 days) and
subsequent treatment with granulocyte colony-stimulating factor (G-CSF,
5–12 μg/kg/day) [4, 11]. Stem cell mobilization is also possible with G-
CSF alone, but may lead to MS relapses [12]. Including cyclosphosphamide
not only increases the efficacy of mobilization, but probably also reduces the
number of autoreactive T cells and inflammatory activity prior to harvesting
stem cells. HSCs are then collected and cryopreserved until transplantation.
Experience has shown that a number of 3×106 CD34+ cells /kg are safe
for the patient [4]. The intermediate-intensity conditioning regimen
BEAM consists of 300 mg/m2 carmustine, at day -6200 mg/m2 etoposide
and 200 mg/m2 cytarabine at days -5 to day -2 and 140 mg/m2 melpha-
lan at day -1. This regimen has shown a good safety/efficacy profile in
lymphoproliferative diseases and in MS was associated to peri-transplant
in vivo iv anti-thymocyte globulin (ATG, 5–7.5 mg/kg in 2–3 days)
(Fig. 2) [3]. Some studies tested a lymphoablative low-intensity regimen
(cyclophosphamide and ATG/alemtuzumab), which shows reduced toxic-
ity, but is less effective in stopping relapse- or in general inflammatory
CNS activity (MRI) [13]. To reduce autoreactive lymphocytes from the
graft different methods have been used, including ex-vivo positive selec-
tion of CD34+ cells prior to cryopreservation. In MS, an evidence of a
clinical benefit of graft manipulation is lacking and mobilization with
cyclophosphamide plus ATG administration as in-vivo T-cell depletion
is now the preferred standard [9]. Besides BEAM-ATG, for which the experience
is currently most extensive, a regimen with busulphan/cyclophosphamide/ATG
combined with positive selection of CD34+ cells of the graft emerges as another
highly effective aHSCT protocol with a good safety profile after the shift to low-
dose, iv busulphan [14].
disease progression (highly active RRMS)
consider aHSCT (patient < 45 years, 2.5 ≤ EDSS ≥ 5.5)
disease progression
escalation therapy (Natalizumab, Fingolimod, others)
MS diagnosis 
start DMD (GA, IFN-β, others)
≤ 5 years from 
initiation of DMD
2.5 ≤ EDSS ≥ 5.5
Fig. 1. Proposed therapy algorithm in multiple sclerosis (Adapted from Mancardi et al. [8]).
Autologous Hematopoietic Stem Cell Transplantation in MS Pfender et al. 275
Adverse events and risks of aHSCT
The transplant-related mortality (TRM) is the major risk for patients under-
going aHSCT in autoimmune diseases (AD). During the first years (1995–
2000) TRM was around 7.4 % but decreased from 2001–2007 to 1.3 %
[4] as experience of the centers have increased, patient selection improved
and toxicity of the protocols decreased. Higher toxicity was observed with
regimens including oral busulphan or whole body irradiation [3]. Conversely
low-intensity treatments posed less toxicity, but were also less effective for
preventing relapses of MS [15]. Pro and contra of myeloablative vs
nonmyeloablative regimens are still controversially discussed [9, 16].
Early side effects are mostly caused by immunosuppression and include
neutropenic fever, sepsis, CMV reactivation, urinary tract infection, gastroen-
teritis, pneumonia, and generalized HSV infection as expected for aHSCT in
other diseases [3]. Other adverse events were allergy to ATG, engraftment syn-
drome, veno-occlusive disease, thrombotic thrombocytopenic purpura and
mucositis, especially in the late phase [3]. Typical long-term risks are devel-
opment of a secondary autoimmune disease (about 12 % of patients
underwent aHSCT for autoimmune disease develop a secondary autoim-
mune disease after a median of 22 months [17]). Only one case with a sec-
ondary malignancy out of 345 MS patients registered in the EBMT database
from 1997–2007 was described [18].
Immune reconstitution and mechanisms of aHSCT
The mechanisms of action of aHSCT are still only partially understood. The
clinical experience of long lasting and complete cessation of disease activity
with improvement of clinical disability in many patients after aHSCT during
the early stages of RRMS suggest that the above premise, ie, elimination of an
d -60 til 
d -30
d -7 d -6, d -4
d -3, d -2
d 0
Cy2-4g/m2 
total, 1-2 days
followed by
G-CSF 5-12 
µg/kg/ day 
until 2-3 x106
CD34+ cells/kg  
harvested
300mg/m2
carmustine
200mg/m2
etoposide
and 
200mg/m2
cytarabine
d -1
140mg/m2
melphalan
d +1
d +2
ATG
5-7.5mg/kg
HSC
infusion
stem cell
mobilization
conditioning regimen HSC infusion T cell 
depletion
time
Fig. 2. Protocol for BEAM/ATG regimen in aHSCT. Stem cell mobilization with cyclophosphamide (Cy) and G-CSF. Conditioning
regimen with carmustine, etoposide, cytarabine, and melphalan, followed by autologous stem cell infusion. In vivo T cell
depletion is performed by anti-thymocyte globulin (ATG).
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aberrant immune system and de novo development of a tolerant/normal im-
mune system, is met and that aHSCT comes close to even curing the disease
[4, 18, 19]. Data from Muraro et al demonstrated in a prospective study of 7
patients receiving an intense conditioning regimen (total body irradiation
and cyclophosphamide), support this notion and showed that the newly
emerging T cell repertoire comes from recent thymic emigrants and is not on-
ly broader, but also indicated complete renewal [20]. Numbers of B cells,
NKTs, and CD3+ T cells were normal with inverted CD4/CD8 ratio within
the first 3 months after aHSCT, whereupon the extra-thymic pathway seems
to be predominant in the first year after aHSCT [20–23]. At this stage
lymphopenia causes homeostatic proliferation, whereas myelin-reactive T
cells undergo activation-induced cell death [24, 25]. While replenishment
of CD4+ T cells lags behind other immune cells during the first year, their
renewal picks up during the second year and overall T cell diversity increases
[26, 27]. Further, similar numbers of myelin basic protein-reactive T cells
were observed after autologous HSCT when compared with before the pro-
cedure, but after 12 months these MBP-reactive T cells showed a more hetero-
geneous epitope recognition pattern than at baseline [28]). Studies in
experimental autoimmune encephalomyelitis (EAE), the main animal model
of MS, demonstrated an increased frequency of regulatory T cells, a shift in T
cell myelin epitope recognition and a reduction of anti-myelin antibodies af-
ter syngeneic bone marrow transplantation [29]. While the above data on T
cell repertoire renewal and elimination of autoreactive T cell clones are rela-
tively complete, there is overall less data on how completely the B cell reper-
toire and antibody profiles are exchanged following aHSCT. Since
oligoclonal immunoglobulin G bands (OCB) in the cerebrospinal fluid are
a diagnostic hallmark of MS and may indicate a certain degree of compart-
mentalization of the autoimmune process in the CNS, it would be important
to examine if they disappear as well as comprehensive profiling of the B cell/
antibody repertoires before and after aHSCT. Preliminary data indicate that
OCB may disappear after aHSCT and remain in some patients, but these
studies are not conclusive at present. When considering the homing of
long-lived plasma cells to the bone marrow and the relative resistance of the-
se cells to chemotherapy, it is possible that even intense regimens may not
completely eliminate them, and that it will then depend on the question if
continued or new disease activity requires T cells or can independently be
driven by pathogenic B-/plasma cells alone. That antibody-producing cells
survive the conditioning regimen is indicated by the at least partially
maintained vaccination status to some antigens after aHSCT (for recommen-
dations regarding vaccination after HSCT see Ljungman et al [30]). Mechanis-
tic reasons for the poor/incomplete response to aHSCT in patients, who have
secondary- or primary progressive disease [3], may relate to the extent of pri-
or damage of CNS tissue, which is then predestined to slowly progressive
neuronal loss and/or to chronic activation of microglial cells and maturation
of reactive astrocytes from glial progenitors in response to the inflammatory
injury in the CNS as shown by Cassiani-Ingoni et al. in the EAE model [31].
According to their data microglia is not or only incompletely affected by
aHSCT.
An important question that relates to the assumption of immune recon-
stitution as basis for the efficacy of aHSCT is if it is likely that patients may re-
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develop MS despite successful immune repertoire exchange since they receive
their own stem cells, which carry in principle the genetic risk factors that pre-
dispose to MS. Clinical experience shows that a small subgroup of patients
indeed re-develop MS even after receiving the currently best aHSCT regimen
[4], however, it is currently not clear if these patients: (a) carry a higher num-
ber of MS risk loci than those, who remain free of new activity; (b) if they
encountered environmental triggering factors; or (c) if the prior damage of
CNS tissue and subsequent death of cells releases autoantigens and this is in-
volved in new disease activity. These questions should be addressed in detail
in the future. As a first step towards examining these issues Lutterotti et al
studied the genome-wide gene expression and microRNA profile of CD34+
hematopoietic precursor cells of MS patients and healthy donors to address
if alterations are already found in these precursor cells. Their results indicate
that there are no significant differences between CD34+ hematopoietic pro-
genitor cells of MS patients and healthy donors [32].
Summary and future directions
During the last two decades aHSCT and its various aspects have been ex-
plored in detail, and the experience can be summarized as follows. Based
on casuistic evidence, data from open and uncontrolled studies and the yet
unpublished controlled comparison of BEAM-ATG vs mitoxantrone aHSCT
(ASTIMS) leads to complete cessation of disease activity in the vast majority
of RRMS patients with aggressive MS fulfilling the above criteria. Further-
more, the ASTIMS data shows even in a small phase IIb study that aHSCT
is significantly more effective than one of the most effective, currently avail-
able drugs, mitoxantrone (Mancardi G, Saccardi R, personal communica-
tion). Furthermore, the risk of transplant-related mortality has dropped to
acceptable levels in this population of patients. Mechanistic studies support
the rationale of aHSCT to abrogate an autoreactive immune repertoire and
re-install a healthy immune system. Despite these clear advances, acceptance
of aHSCT in the neurological community remains low probably due to the
continuing false perception of unacceptable risk, the complexity of the treat-
ment, which requires close interaction between MS neurologists and hema-
tologist/transplant specialist, and the increasing number of treatments that
offer a good compromise of acceptable benefit/risk ratio and easier adminis-
tration. Despite the latter, existing data indicate that even the most effective
available drugs need to be given continuously, that particularly the most ef-
fective therapies carry substantial risk, and that they are expected to be infe-
rior to aHSCT regarding their efficacy. Further, aHSCT is a one time treatment
with no need for continuing immunomodulation, and, when considering the
cost of currently available treatments of up to 45,000 USD/year, will lead to
substantial socioeconomic benefit in patients with aggressive MS. What is
needed most, however, is definitive evidence for superiority of aHSCT over
best available therapy of MS by a controlled, multi-center trial. Following
several years of intense discussions among European and North-American in-
vestigators the main aspects of such a trial have now been outlined and re-
cently published [9]. Since a phase III trial of aHSCT vs conventional
treatment will not be sponsored by industry, the main challenge ahead is
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to raise interest and funds from public organizations, eg, the European Com-
munity in order to provide the missing evidence.
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